title: Where does current and future pediatric asthma treatment stand? Remodeling and inflammation: Bird's eye view.
abstract: Airway remodeling is the chronic outcome of inflammation in asthma and a point of intervention between pediatric and adult ages. Pediatric asthma has been of great interest in the efforts to find a valuable time to interrupt remodeling. Various experimental and clinical research have assessed the effect of current therapeutic modalities on airway remodeling in asthma and many new agents are being developed with promising results. The heterogeneity in the results of these studies may lie in the heterogeneity of pathogenesis leading to asthma and remodeling; underlying the need for individualized treatment of the unique pathogenetic characteristics of each child's asthma. The aim of this review is to summarize the evidence about the influence of current and future therapeutic modalities in the concept of inflammation and remodeling in pediatric asthma. Pediatr Pulmonol. 2016;51:1422-1429. © 2016 Wiley Periodicals, Inc.
authors.affiliation: Department of Pediatric Allergy and Pulmonology, Celal Bayar University Medical Faculty, Manisa, Turkey.
authors.forename: Ozge
authors.initials: O
authors.lastname: Yilmaz
authors.affiliation: Department of Pediatric Allergy and Pulmonology, Celal Bayar University Medical Faculty, Manisa, Turkey.
authors.forename: Hasan
authors.initials: H
authors.lastname: Yuksel
mesh_terms: D000280:Administration, Inhalation; D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use*; D056151:Airway Remodeling / Q000276:immunology / Q000502:physiology*; D018927:Anti-Asthmatic Agents / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D001993:Bronchodilator Agents / Q000627:therapeutic use*; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D016207:Cytokines / Q000276:immunology; D006801:Humans; D007223:Infant; D007249:Inflammation / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D015848:Interleukin-5 / Q000037:antagonists & inhibitors; D020024:Leukotriene Antagonists / Q000627:therapeutic use*; D000069444:Omalizumab / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014807:Vitamin D / Q000627:therapeutic use; D014815:Vitamins / Q000627:therapeutic use
chemical_list: D000305:Adrenal Cortex Hormones; D018927:Anti-Asthmatic Agents; D061067:Antibodies, Monoclonal, Humanized; D001993:Bronchodilator Agents; D002121:Calcium Channel Blockers; D016207:Cytokines; D015848:Interleukin-5; D020024:Leukotriene Antagonists; D014409:Tumor Necrosis Factor-alpha; D042461:Vascular Endothelial Growth Factor A; D014815:Vitamins; D014807:Vitamin D; D000069444:Omalizumab; C434107:mepolizumab
keywords: Pediatric asthma; current; future; inflammation; remodeling; treatment